Literature DB >> 20427537

Two domains of the V protein of virulent canine distemper virus selectively inhibit STAT1 and STAT2 nuclear import.

Anne Röthlisberger1, Dominique Wiener, Matthias Schweizer, Ernst Peterhans, Andreas Zurbriggen, Philippe Plattet.   

Abstract

Canine distemper virus (CDV) causes in dogs a severe systemic infection, with a high frequency of demyelinating encephalitis. Among the six genes transcribed by CDV, the P gene encodes the polymerase cofactor protein (P) as well as two additional nonstructural proteins, C and V; of these V was shown to act as a virulence factor. We investigated the molecular mechanisms by which the P gene products of the neurovirulent CDV A75/17 strain disrupt type I interferon (IFN-alpha/beta)-induced signaling that results in the establishment of the antiviral state. Using recombinant knockout A75/17 viruses, the V protein was identified as the main antagonist of IFN-alpha/beta-mediated signaling. Importantly, immunofluorescence analysis illustrated that the inhibition of IFN-alpha/beta-mediated signaling correlated with impaired STAT1/STAT2 nuclear import, whereas the phosphorylation state of these proteins was not affected. Coimmunoprecipitation assays identified the N-terminal region of V (VNT) responsible for STAT1 targeting, which correlated with its ability to inhibit the activity of the IFN-alpha/beta-mediated antiviral state. Conversely, while the C-terminal domain of V (VCT) could not function autonomously, when fused to VNT it optimally interacted with STAT2 and subsequently efficiently suppressed the IFN-alpha/beta-mediated signaling pathway. The latter result was further supported by a single mutation at position 110 within the VNT domain of CDV V protein, resulting in a mutant that lost STAT1 binding while retaining a partial STAT2 association. Taken together, our results identified the CDV VNT and VCT as two essential modules that complement each other to interfere with the antiviral state induced by IFN-alpha/beta-mediated signaling. Hence, our experiments reveal a novel mechanism of IFN-alpha/beta evasion among the morbilliviruses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20427537      PMCID: PMC2903251          DOI: 10.1128/JVI.01878-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  The paramyxovirus SV5 V protein binds two atoms of zinc and is a structural component of virions.

Authors:  R G Paterson; G P Leser; M A Shaughnessy; R A Lamb
Journal:  Virology       Date:  1995-04-01       Impact factor: 3.616

2.  Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain.

Authors:  M Kawano; M Kaito; Y Kozuka; H Komada; N Noda; K Nanba; M Tsurudome; M Ito; M Nishio; Y Ito
Journal:  Virology       Date:  2001-05-25       Impact factor: 3.616

Review 3.  Stats: transcriptional control and biological impact.

Authors:  David E Levy; J E Darnell
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

4.  Single amino acid substitution in the V protein of simian virus 5 differentiates its ability to block interferon signaling in human and murine cells.

Authors:  D F Young; N Chatziandreou; B He; S Goodbourn; R A Lamb; R E Randall
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Measles virus suppresses interferon-alpha signaling pathway: suppression of Jak1 phosphorylation and association of viral accessory proteins, C and V, with interferon-alpha receptor complex.

Authors:  Shin-ichi Yokota; Hiroyuki Saito; Toru Kubota; Noriko Yokosawa; Ken-ichi Amano; Nobuhiro Fujii
Journal:  Virology       Date:  2003-02-01       Impact factor: 3.616

6.  High resistance of human parainfluenza type 2 virus protein-expressing cells to the antiviral and anti-cell proliferative activities of alpha/beta interferons: cysteine-rich V-specific domain is required for high resistance to the interferons.

Authors:  M Nishio; M Tsurudome; M Ito; M Kawano; H Komada; Y Ito
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  The V protein of human parainfluenza virus 2 antagonizes type I interferon responses by destabilizing signal transducer and activator of transcription 2.

Authors:  J P Parisien; J F Lau; J J Rodriguez; B M Sullivan; A Moscona; G D Parks; R A Lamb; C M Horvath
Journal:  Virology       Date:  2001-05-10       Impact factor: 3.616

8.  Selective STAT protein degradation induced by paramyxoviruses requires both STAT1 and STAT2 but is independent of alpha/beta interferon signal transduction.

Authors:  Jean-Patrick Parisien; Joe F Lau; Jason J Rodriguez; Christina M Ulane; Curt M Horvath
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

9.  STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling.

Authors:  Christina M Ulane; Jason J Rodriguez; Jean-Patrick Parisien; Curt M Horvath
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Inhibition of IFN-alpha/beta signaling by two discrete peptides within measles virus V protein that specifically bind STAT1 and STAT2.

Authors:  Grégory Caignard; Mehdi Bouraï; Yves Jacob; Frédéric Tangy; Pierre-Olivier Vidalain
Journal:  Virology       Date:  2008-11-12       Impact factor: 3.616

View more
  26 in total

1.  The measles virus V protein binds to p65 (RelA) to suppress NF-kappaB activity.

Authors:  Kerstin M Schuhmann; Christian K Pfaller; Karl-Klaus Conzelmann
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

2.  Full genome sequence of a peste des petits ruminants virus (PPRV) from Ghana.

Authors:  W G Dundon; C Adombi; A Waqas; H R Otsyina; C T Arthur; R Silber; A Loitsch; A Diallo
Journal:  Virus Genes       Date:  2014-08-24       Impact factor: 2.332

Review 3.  Paramyxovirus evasion of innate immunity: Diverse strategies for common targets.

Authors:  Michelle D Audsley; Gregory W Moseley
Journal:  World J Virol       Date:  2013-05-12

4.  Mechanism for active membrane fusion triggering by morbillivirus attachment protein.

Authors:  Nadine Ader; Melinda Brindley; Mislay Avila; Claes Örvell; Branka Horvat; Georg Hiltensperger; Jürgen Schneider-Schaulies; Marc Vandevelde; Andreas Zurbriggen; Richard K Plemper; Philippe Plattet
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

Review 5.  Modulation of Host Immunity by the Human Metapneumovirus.

Authors:  Pablo F Céspedes; Christian E Palavecino; Alexis M Kalergis; Susan M Bueno
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

6.  La Piedad Michoacán Mexico Virus V protein antagonizes type I interferon response by binding STAT2 protein and preventing STATs nuclear translocation.

Authors:  Giuseppe Pisanelli; Maudry Laurent-Rolle; Balaji Manicassamy; Alan Belicha-Villanueva; Juliet Morrison; Bernardo Lozano-Dubernard; Felipa Castro-Peralta; Giuseppe Iovane; Adolfo García-Sastre
Journal:  Virus Res       Date:  2015-11-03       Impact factor: 3.303

7.  Morbillivirus control of the interferon response: relevance of STAT2 and mda5 but not STAT1 for canine distemper virus virulence in ferrets.

Authors:  Nicholas Svitek; Ingo Gerhauser; Christophe Goncalves; Elena Grabski; Marius Döring; Ulrich Kalinke; Danielle E Anderson; Roberto Cattaneo; Veronika von Messling
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

8.  Morbillivirus v proteins exhibit multiple mechanisms to block type 1 and type 2 interferon signalling pathways.

Authors:  Senthil K Chinnakannan; Sambit K Nanda; Michael D Baron
Journal:  PLoS One       Date:  2013-02-19       Impact factor: 3.240

Review 9.  Evolutionary history of cotranscriptional editing in the paramyxoviral phosphoprotein gene.

Authors:  Jordan Douglas; Alexei J Drummond; Richard L Kingston
Journal:  Virus Evol       Date:  2021-03-27

10.  Experimental adaptation of wild-type canine distemper virus (CDV) to the human entry receptor CD150.

Authors:  Maria Bieringer; Jung Woo Han; Sabine Kendl; Mojtaba Khosravi; Philippe Plattet; Jürgen Schneider-Schaulies
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.